NCT06561126 Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]
| NCT ID | NCT06561126 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Khyber Medical University Peshawar |
| Condition | Type II Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 12,744 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12,744 participants in total. It began in 2025-05-01 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to adapt, implement, and evaluate Participatory Learning and Action (PLA) based intervention in rural areas of KPK, Pakistan which includes Peshawar and Swabi for TIIDM prevention and control. The pivotal components of this approach include adapting, implementing, and evaluating the PLA-based intervention for the prevention and control of Type II diabetes. These components will be tailored to meet the specific needs of two different settings in Peshawar and Swabi, Pakistan. Type II Diabetes Mellitus (TIIDM) is considered the fastest-growing health emergency, affecting 537 million adults worldwide. Global projections for the year 2045 suggest that a 12.2% rise in TIIDM is anticipated with an additional 11.4% rise for intermediate hyperglycemia (IHG) \[1\]. Around 80% of people with TIIDM reside in low-and middle-income countries (LMICs), exhausting the already burdened healthcare system \[2\]. The intervention "Community groups or mobile phone messaging to prevent and control type 2 diabetes and intermediate hyperglycemia in Bangladesh (DMagic)" has been tested and found effective in the rural context of Bangladesh \[1-3\]. A full trial will be conducted in the rural areas of Peshawar and Swabi, Pakistan. It is anticipated that with the use of evidence-based approaches, best practices, and meaningful community participation, PLA is expected to enhance social and behavioural determinants of health and subsequent outcomes. This will further pave the way for the control of other NCDs through a similar focused approach.
Eligibility Criteria
Inclusion Criteria: * Individuals aged 20 years and above. * Participants residing in the rural areas of Peshawar and Swabi, Pakistan. * Individuals willing to participate in the study and provide consent. * Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate. * Participants who can attend the scheduled meetings and interventions as per the study protocol. Exclusion Criteria: * Individuals below the age of 20 years. * Individuals unwilling to provide consent for participation. * Participants with severe health conditions that may hinder their active involvement in the study. * Individuals with a history of non-compliance with medical interventions or research protocols
Contact & Investigator
Prof. Dr Zia Ul Haq, MBBS,MPH,PhD
PRINCIPAL INVESTIGATOR
Khyber Medical Univeristy Peshawar
Frequently Asked Questions
Who can join the NCT06561126 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Type II Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06561126 currently recruiting?
Yes, NCT06561126 is actively recruiting participants. Contact the research team at drzia@kmu.edu.pk for enrollment information.
Where is the NCT06561126 trial being conducted?
This trial is being conducted at Peshawar, Pakistan.
Who is sponsoring the NCT06561126 clinical trial?
NCT06561126 is sponsored by Khyber Medical University Peshawar. The principal investigator is Prof. Dr Zia Ul Haq, MBBS,MPH,PhD at Khyber Medical Univeristy Peshawar. The trial plans to enroll 12,744 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.